App-Quantinova.ai

Evaluation of tumor- and stromal immune marker heterogeneity in lung adenocarcinoma.

David Casadevall - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Clinical significance of the tumor expression of PD-L1 in lung cancer.

Luigi De Petris - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Programmed DeathLigand 1 (PD-L1) immumohistochemistry in NSCLC: Comparison and correlation between two antibodies.

Gareth Rivalland - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Comprehensive gene analysis including next generation sequencing (NGS) study with immunological parameters to obtain the biomarkers for immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).

Yuki Owada - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Incidence of ALK, cKIT, cMET, EGFR, PD1/PD-L1, and JAK3 alterations in 170 malignant pleural mesotheliomas (MPM) and 102 peritoneal mesotheliomas.

David Arguello - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs).

Arun Rajan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Thymic epithelial tumors

Avelumab

Expression of PD-L1, PD-L2 and PD-1 in thymic epithelial tumours (TETs).

Spyridon Gennatas - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Epithelial tumors

N/A

Analysis of PD-L1 and RAD50 in circulating cells recovered from lung cancer patients before and after induction of radiotherapy.

Daniel L Adams - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with advanced NSCLC: A meta-analysis.

Gaetan Des Guetz - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Pembrolizumab

Correlation of PD-L1 expression with EGFR, KRAS, or ALK alterations and with survival of non-small cell lung cancer (NSCLC) treated with EGFR-TKIs: A meta-analysis of published trials.

Dianhe Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Programmed cell death ligand 1(PD-L1), Programmed death 1+(PD-1) lymphocytes and Tumor infiltrating lymphocytes (TILs): are they playing a role in predicting response to anti-PD-1 therapies?

Chiara Bennati - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Nivolumab

Clinicopathologic features of best and worst responders to PD1/PDL1 checkpoint inhibitors (CPIs) in non-small-cell lung cancer (NSCLC).

Dawn Michelle Stults - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Preliminary results of ENCORE 601, a phase 1b/2, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC).

Melissa Lynne Johnson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Pembrolizumab

Liver metastases and sensitivity to checkpoint inhibition in patients with non-small cell lung cancer (NSCLC).

Rathi Narayana Pillai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Correlation between PD-L1 expression and PD-1 immune checkpoint blockade: A retrospective analysis for advanced melanoma.

Jinhyun Cho - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

N/A

Cyclooxygenase inhibition and response to anti-PD1/L1 in advanced melanoma.

Romany Anne Nilanthi Johnpulle - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

N/A

SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma.

Kenneth F. Grossmann - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

Interferon

Patterns of PD-L1 expression on circulating tumor cells in Japanese patients with advanced lung cancer.

Yasuhiro Koh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.

Toshiyuki Ishiba - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

PD-L1 expression and possibility of its therapeutic target in cutaneous angiosarcoma.

Kyoichi Kaira - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Angiosarcoma

N/A

Filters

4177 Abstracts